New York Reports First Measles-Associated Child Death in Over 30 Years Amid Growing Outbreak
The latest measles cases USA November 2026 reports, led by a New York child death, raise questions for vaccine makers and public health budgets.
New York Reports First Measles-Associated Child Death in Over 30 Years Amid Growing Outbreak
The latest measles cases USA November 2026 reports, led by a New York child death, raise questions for vaccine makers and public health budgets.
Delhi High Court Restrains NPPA From Recovering ₹151 Crore From AstraZeneca in Symbicort Pricing Case
The AstraZeneca ₹151 crore case shows how classification disputes can create pricing liabilities for drugmakers in India; recovery is paused until 11 January.
Vertex Q3 2026 Results: Revenue Rises 12% as Crinetics Deal Reshapes Cash, Margins and Guidance
A business read of the Vertex Q3 2026 results: revenue mix, margins, the $10 billion Crinetics deal, cash and a small guidance raise.
Recursion REC-4881 Phase 2 Results: What the FAP Data, Cash Runway and Partner Milestones Mean for the AI Biotech
The Recursion REC-4881 Phase 2 results meet a $748.7 million pro forma cash pile and new partner milestones. A business read of the AI biotech story.
Nova StatStrip Glucose Meter FDA Update: What the Gen 2.0 Software Issue Means for Hospitals and the Maker
The Nova StatStrip glucose meter FDA update could pull Gen 2.0 meters from wards. Operational impact, commercial exposure and open questions.
HemosIL AcuStar Recall: What the FDA Class I Action Means for Werfen, Labs and Diagnostics Supply
The HemosIL AcuStar recall puts Werfen under a Class I FDA action. Supply disruption, customer trust and what is still unknown.
Narayana Health Q2 Results FY27: Revenue Up 73%, but Organic Growth Is 22.6% as UK Deal Dilutes Margins
The Narayana Health Q2 results FY27: 73% revenue growth, 22.6% without the UK. A business look at margins, finance costs and what to watch.
Rainbow Children’s Medicare Q2 FY27 Results: Revenue Up 23% as Expansion Squeezes Margins
The Rainbow Children Q2 FY27 results: revenue up 23%, profit up 11%. A business look at expansion costs, margins and what comes next.
Assam Proton Therapy Centre: Financing, Utilisation and Execution Risks of a ₹600 Crore Public Project
The Assam proton therapy centre is a ₹600 crore public bet. Financing split, utilisation questions and execution risks.
